Literature DB >> 2120285

Interferon-gamma overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis by murine macrophages.

C E Luedke1, A Cerami.   

Abstract

Glucocorticoids almost completely inhibit the synthesis by isolated macrophages of cachectin/tumor necrosis factor (TNF), a cytokine implicated as a major endogenous mediator of septic shock. Despite this in vitro effectiveness, the clinical use of glucocorticoids has failed to demonstrate any clear benefit in the treatment of septic shock. In an effort to understand what other mechanisms might play a role in the patient with sepsis, we examined the effect of interferon-gamma (IFN gamma) on the synthesis of cachectin/TNF. We show here that IFN gamma, although unable by itself to induce cachectin/TNF synthesis, enhanced the endotoxin-induced production of cachectin/TNF in vitro. Furthermore, IFN gamma overcame the inhibition of cachectin/TNF synthesis caused by the glucocorticoid, dexamethasone. These effects of IFN gamma were accounted for by increased levels of cachectin/TNF mRNA. The in vivo implications of these studies are discussed with emphasis on their relevance in human sepsis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120285      PMCID: PMC296853          DOI: 10.1172/JCI114829

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Recovery from lethal Escherichia coli shock in dogs.

Authors:  L B Hinshaw; B K Beller; L T Archer; D J Flournoy; G L White; R W Phillips
Journal:  Surg Gynecol Obstet       Date:  1979-10

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Cytoplasmic dot hybridization. Simple analysis of relative mRNA levels in multiple small cell or tissue samples.

Authors:  B A White; F C Bancroft
Journal:  J Biol Chem       Date:  1982-08-10       Impact factor: 5.157

4.  Steroids in the treatment of clinical septic shock.

Authors:  W Schumer
Journal:  Ann Surg       Date:  1976-09       Impact factor: 12.969

5.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura.

Authors:  E Girardin; G E Grau; J M Dayer; P Roux-Lombard; P H Lambert
Journal:  N Engl J Med       Date:  1988-08-18       Impact factor: 91.245

6.  Evidence for the identity of murine gamma interferon and macrophage activating factor.

Authors:  W K Roberts; A Vasil
Journal:  J Interferon Res       Date:  1982

7.  Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon.

Authors:  R D Schreiber; J L Pace; S W Russell; A Altman; D H Katz
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

8.  Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing.

Authors:  J L Pace; S W Russell; B A Torres; H M Johnson; P W Gray
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

9.  Current management of the septic shock patient: experimental basis for treatment.

Authors:  L B Hinshaw; B K Beller-Todd; L T Archer
Journal:  Circ Shock       Date:  1982

10.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.

Authors:  C F Nathan; H W Murray; M E Wiebe; B Y Rubin
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  18 in total

Review 1.  Sepsis-induced immunosuppression: from bad to worse.

Authors:  R C Reddy; G H Chen; P K Tekchandani; T J Standiford
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  A novel mechanism of glucocorticoid-induced immune suppression: the inhibiton of T cell-mediated terminal maturation of a murine dendritic cell line.

Authors:  T Kitajima; K Ariizumi; P R Bergstresser; A Takashima
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

3.  Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy.

Authors:  G Fingerle-Rowson; M Angstwurm; R Andreesen; H W Ziegler-Heitbrock
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

4.  Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats.

Authors:  K kerlund; H Erlandsson Harris; K J Tracey; H Wang; T Fehniger; L Klareskog; J Andersson; U Andersson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

5.  Gamma interferon mediates Propionibacterium acnes-induced hypersensitivity to lipopolysaccharide in mice.

Authors:  T Katschinski; C Galanos; A Coumbos; M A Freudenberg
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

6.  Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages.

Authors:  B Sherry; N Yarlett; A Strupp; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

7.  Dexamethasone prevents autoimmune nephritis and reduces renal expression of Ia but not costimulatory signals.

Authors:  A M Jevnikar; G G Singer; D C Brennan; H W Xu; V R Kelley
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

8.  Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture.

Authors:  G K Wollenberg; L E DeForge; G Bolgos; D G Remick
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

9.  Induction of the chemokine beta peptides, MIP-1 alpha and MIP-1 beta, by lipopolysaccharide is differentially regulated by immunomodulatory cytokines gamma-IFN, IL-10, IL-4, and TGF-beta.

Authors:  B Sherry; M Espinoza; K R Manogue; A Cerami
Journal:  Mol Med       Date:  1998-10       Impact factor: 6.354

10.  Dexamethasone protection of rat intestinal epithelial cells against oxidant injury is mediated by induction of heat shock protein 72.

Authors:  S Urayama; M W Musch; J Retsky; M B Madonna; D Straus; E B Chang
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.